Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes

二维码有效期 120s

摘要篇首： Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders characterized by ineffective hematopoiesis; they manifest clinically as anemia, neutropenia, and thrombocytopenia.

作者单位 Institute of Hematology, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003,China ^[1]

关键词 myelodysplastic syndromes high-intensity chemotherapy induction homoharringtonine

分类号 R3

栏目名称

CLINICAL EXPERIENCE

DOI 10.3760/cma.j.issn.0366-6999.2010.01.020

发布时间 2010-03-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览145
被引5
下载0

中华医学杂志（英文版）

2010年123卷1期

108-110页

SCIMEDLINEISTICCSCDCABP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes

中华医学杂志（英文版）

相似文献

中华医学杂志（英文版）

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes

中华医学杂志（英文版）

相似文献

中华医学杂志（英文版）

相关期刊

检索历史清除